中国P站

Abstract

Colorectal cancer research is rapidly advancing across multiple fronts. Studies address the rising incidence of early-onset disease, advocating for updated screening guidelines. Personalized medicine, immune checkpoint inhibitors, \textit{Artificial Intelligence} (AI), and nanotechnology are revolutionizing treatment and diagnostics. Liquid biopsies offer new detection and monitoring capa bilities. Furthermore, understanding the interplay of gut microbiota and genetic predispositions is improving targeted therapies and risk assessment. Lifestyle factors remain key for primary prevention, highlighting a comprehensive approach to combat this complex disease and improve patient outcomes.